AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00377364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Acetaminophen, Drug: Placebo
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
Study NCT00377364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Acetaminophen, Drug: Placebo
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
Study NCT02145351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive atrial pacing using a dual-chamber pacemaker
Description: The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
Study NCT02145351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate adaptive atrial pacing using a dual-chamber pacemaker
Description: The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
Study NCT02145351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker system will be implanted but set to Pacing Off.
Description: The identical pacing system will be implanted, but will be set to Pacing Off.
Study NCT02145351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker system will be implanted but set to Pacing Off.
Description: The identical pacing system will be implanted, but will be set to Pacing Off.
Study NCT02774499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
Study NCT02774499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume (5mL) of syrup given preoperatively
Study NCT01970384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: 20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
Study NCT01970384 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
Study NCT00758316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracoscopy and Pleurx
Description: Talc poudrage and tunneled pleural catheter
Study NCT00758316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy
Description: Talc poudrage
Study NCT02204267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged ECG monitoring
Description: Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
Study NCT02204267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG
Study NCT02497599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111-DOTA-Girentuximab-IRDye800CW
Description: Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
Study NCT02497599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: 4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
Study NCT02497599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative dual-modality imaging
Description: 7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
Study NCT04467138 — intervention group
Intervention type: DRUG
Intervention: Omegaven
Description: Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
Study NCT01872104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
Study NCT00570622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Patients receive 60mg of pioglitazone once a day orally for 9 days
Study NCT00570622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo once a day orally for 9 days
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 100ug, every 12 hours (twice a day)
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 300ug, every 12 hours (twice a day)
Study NCT03014349 — intervention group
Intervention type: OTHER
Intervention: Analysis of medical records
Description: Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 1mg, every 12 hours (twice a day)
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00885706
Description: Capsule, 3mg, every 12 hours (twice a day)
Study NCT03855514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NuShield
Description: NuShield® is a dehydrated placental allograft.
Study NCT02053714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes self-management and education
Study NCT03662841 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablative chemoembolization (ACE)
Description: Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Experimental Interventional Therapy
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study NCT01867463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra
Description: Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
Study NCT03998397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood alcohol concentration withdrawal
Description: The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
Study NCT00732485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
Study NCT00732485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, sugar pill, from admission to 6 months post burn
Study NCT03938909 — intervention group
Intervention type: GENETIC
Intervention: cif mtDNA biomarker
Description: The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody
Study NCT04245722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study NCT00098774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
Study NCT00730665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Placebo, every 12 hours (twice a day)
Study NCT00730665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
Study NCT04042727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
Study NCT04042727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
Study NCT02939326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection
Study NCT00445965 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody 3F8
Study NCT00445965 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-3F8
Description: Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
Study NCT02586896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based Case Management (SBCM)
Description: The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
Study NCT02939326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Study NCT03384394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow nasal cannula oxygen
Description: high-flow nasal cannula oxygen
Study NCT03384394 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional oxygen therapy
Description: oxygen by a standard nasal cannula or nonrebreather mask
Study NCT03795324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redlove Apple intervention
Description: The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
Study NCT03795324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Apple intervention
Description: It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
Study NCT03795324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia drink intervention
Description: The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
Study NCT00098774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2
Study NCT00098774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
Study NCT00098774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
Study NCT01440231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by subcutaneous injection, once weekly
Study NCT01440231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 5 mg administered by subcutaneous injection, once weekly
Study NCT01440231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 25 mg administered by subcutaneous injection, once weekly
Study NCT01440231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 75 mg administered by subcutaneous injection, once weekly
Study NCT01440231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 115 mg administered by subcutaneous injection, once weekly
Study NCT03812614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAM ACT
Description: Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
Study NCT03812614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-DSMES
Description: Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
Study NCT00642317 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
Study NCT04132674 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Taking one oral tablet of B/F/TAF once-daily for 72 weeks
Study NCT02229526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose fish oil
Description: Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
Study NCT02229526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low dose olive oil
Description: Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
Study NCT02229526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose fish oil
Description: Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
Study NCT02229526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High dose olive oil
Description: Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
Study NCT03951116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437
Description: FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Study NCT05825885 — intervention group
Intervention type: DRUG
Intervention: E2
Description: micronized E2 at a daily dose of 4-6mg,
Study NCT03137329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise program
Description: Physical therapy for aerobic and resistance training exercises
Study NCT03137329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrition
Description: Nutrition supplementation via HMR for lifestyle arm only
Study NCT03137329 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: WLS
Description: Weight loss surgery as planned
Study NCT02195895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Weekly oral alendronate 70 mg for 12 months
Study NCT02195895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Daily oral 1000 mg Calcium
Study NCT02195895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily oral 1000 IU
Study NCT04421430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction cards
Description: The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
Study NCT04421430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
Study NCT04421430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
Study NCT01343732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS
Description: deep transcranial magnetic stimulation